Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

The use of androgen deprivation therapy may hasten the development of acute kidney injury in prostate cancer patients.

​This study examined the correlation between the intake of androgen deprivation drugs and the incidence of acute kidney injury (AKI) in patients newly diagnosed with prostate cancer. Researchers surveyed more than 10,000 prostate cancer patients for an average of 4.1 years. During the course of the study, 231 cases of acute kidney injury were recorded. 

Researchers noted that prostate cancer patients treated with androgen deprivation therapy (ADT) were more likely to suffer from acute kidney injury compared to their counterparts who did not use these drugs. This study concluded that "In a cohort of patients with newly diagnosed nonmetastatic prostate cancer, the use of ADT was significantly associated with an increased risk of AKI."